Abstract:
:No studies have reported the long-term effects of entecavir switching in patients with multidrug resistance who developed resistance after lamivudine/adefovir sequential therapy. We evaluated the efficacy of 96 weeks of entecavir therapy in patients with resistance to lamivudine/adefovir sequential therapy. In total, 33 patients with chronic hepatitis B virus (HBV) infection with evidence of active viral replication (HBV DNA levels ≥ 10(5) copies/mL) or a history of treatment failure to lamivudine/adefovir sequential therapy between April 2007 and July 2009 were treated with entecavir (1.0 mg daily) for at least 48 weeks. The rates of alanine transaminase (ALT) normalization and HBV DNA negativity were 66.7% (14/21) and 24.2% (8/33) at 48 weeks, respectively. The initial HBV DNA level was the only factor that was inversely associated with serum HBV DNA negativity after 48 weeks of entecavir therapy (P < 0.023). At 96 weeks, the rates of ALT normalization and HBV DNA negativity were 77.8% (7/9) and 16.7% (3/18), respectively. Viral breakthrough occurred in 21.2% (7/33) and 78.9% (15/19) of patients at 48 and 96 weeks, respectively. Patients who achieved a HBV DNA level of <4 log(10) copies/mL at 48 weeks maintained a similar HBV DNA level and a normal ALT level until 96 weeks. Entecavir monotherapy for 96 weeks was not efficacious for patients with lamivudine/adefovir-resistant HBV. The initial HBV DNA level was the only predictive factor for antiviral efficacy. However, patients who achieved a HBV DNA level of <4 log(10) copies/mL with a normal ALT level at 48 weeks should maintain, rather than stop, entecavir therapy.
journal_name
J Viral Hepatjournal_title
Journal of viral hepatitisauthors
Kwak MS,Choi JW,Lee JS,Kim KA,Suh JH,Cho YS,Won SY,Park BK,Lee CKdoi
10.1111/j.1365-2893.2011.01461.xsubject
Has Abstractpub_date
2011-10-01 00:00:00pages
e432-8issue
10eissn
1352-0504issn
1365-2893journal_volume
18pub_type
杂志文章abstract::Transcription of p21 was activated in hepatitis C virus (HCV) Core-expressing HepG2 cells where its upstream p53 was stabilized. However, this effect was not absolutely required for the activation of p21 by Core, as demonstrated in Hep3B cells. In addition, an opposite effect on the transcription of p21 was observed i...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1046/j.1365-2893.2003.00434.x
更新日期:2003-07-01 00:00:00
abstract::Pegylated interferon-α (PEG-IFN-α) plus ribavirin (RBV) treatment fails to achieve a sustained virological response (SVR) in approximately 20-50% of patients with chronic hepatitis C virus (HCV) infection. We assessed the contribution of an anti-IFN-α neutralizing antibody (NAb) on the nonresponse to treatment. NAbs w...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2012.01598.x
更新日期:2012-10-01 00:00:00
abstract::Autoantibodies are commonly detected in chronic hepatitis C (HCV) but their significance remains uncertain. We assessed the prevalence of anti-nuclear (ANA) and anti-smooth muscle (ASM) antibodies within a cohort of 963 treatment-naïve HCV patients. We also assessed for differences between autoantibody-positive and au...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2008.01035.x
更新日期:2009-05-01 00:00:00
abstract::The establishment of an in vitro system for hepatitis C virus (HCV) propagation is essential to characterize virus replication, virus persistence and viral pathogenicity. The aim was to establish HCV replication in HepG2 cells by gene transfer of infectious HCV cDNA. First, several gene transfer methods were evaluated...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.1997.tb00162.x
更新日期:1997-01-01 00:00:00
abstract::Drug users with chronic hepatitis C virus (HCV) infection are frequently co-infected with human immunodeficiency virus-1 (HIV-1), but it is still not clear whether HIV-1 worsens the natural history of hepatitis C. To investigate this, we conducted a multicentre observational study in 163 drug addicts with histological...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1046/j.1365-2893.2000.00230.x
更新日期:2000-07-01 00:00:00
abstract::It is unknown whether dynamic changes of liver stiffness measurement (LSM) can predict the reversibility of fibrosis. Therefore, we evaluated the utility of LSM changes in predicting histological changes of fibrosis in patients with chronic hepatitis B (CHB) on antiviral therapy. In a prospective cohort of CHB patient...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.13058
更新日期:2019-05-01 00:00:00
abstract::Italy is one of the countries on track with the WHO's agenda to eliminate hepatitis C virus (HCV) by 2030. Healthcare facilities play a crucial role in seeking patients who are infected but have not yet been treated. We assessed the effectiveness of a recall strategy, named 'Telepass' project, for patients exposed to ...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.13465
更新日期:2021-01-09 00:00:00
abstract::The impact of direct-acting antiviral (DAA) therapies on fibrosis regression remains uncertain. In the current study, we prospectively evaluated dynamics of liver stiffness by transient elastography (TE) in patients with chronic HCV infection receiving DAA-based treatment. Patients (260) were enrolled in the German He...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.13280
更新日期:2020-07-01 00:00:00
abstract::Women with chronic hepatitis B should maintain nucleotide analogue treatment to prevent disease progression during pregnancy. The aim of this study was to prospectively evaluate the efficacy and safety of telbivudine used throughout pregnancy for preventing hepatitis B virus (HBV) mother-to-child transmission (MTCT). ...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.12788
更新日期:2017-11-01 00:00:00
abstract::Seroconversion from hepatitis B surface antigen (HBsAg) to antibodies against HBsAg (anti-HBs) usually indicates resolution of hepatitis B virus (HBV) infection. Here, two HBV-infected patients with seroconversion to anti-HBs were found to be persistently positive for HBeAg and HBV DNA. Immunohistology of liver biopsi...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2010.01322.x
更新日期:2011-06-01 00:00:00
abstract::Limited data suggest that low T-helper cell levels may be observed in hepatitis C virus (HCV) monoinfected patients with decompensated liver disease. We sought to determine the distribution and relationship of T-helper cells (CD4) to liver fibrosis in HCV-monoinfected patients before and during pegylated interferon (P...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2009.01173.x
更新日期:2010-03-01 00:00:00
abstract::In 1996, a combined vaccine against both hepatitis A and B was licensed and commercialized and has been recommended for healthcare personnel in Belgium. This study compares the immunogenicity against hepatitis B virus (HBV) and safety of two vaccination schedules (0-1-12 months and 0-1-6 months) with this vaccine. Thi...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,随机对照试验
doi:10.1111/j.1365-2893.2010.01365.x
更新日期:2011-04-01 00:00:00
abstract::Hepatocellular carcinoma (HCC) is the most common complication of HCV infection leading to liver transplantation. We evaluated the impact of aetiology of liver disease on patient and graft survival following liver transplantation for HCC. From the Scientific Registry of Transplant Recipients (2002-2011), all adults wh...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.12449
更新日期:2016-01-01 00:00:00
abstract::Hepatitis C virus (HCV) infection is currently the most important cause of chronic viral hepatitis in the world and one of the most frequent indications for liver transplantation. HCV uses different strategies to evade the innate and adaptive immune response, and this evasion plays a key role in determining viral pers...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,评审
doi:10.1111/jvh.12675
更新日期:2017-05-01 00:00:00
abstract::Chronic hepatitis C infection leads to increased hepatocyte apoptosis. Because engulfment of apoptotic bodies (ABs) by hepatic stellate cells (HSC) is profibrogenic, we compared the effects of ABs derived from hepatitis C virus (HCV)-negative vs HCV-infected (Con1+) Huh7 hepatoblastoma cells on fibrogenic and activati...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2010.01362.x
更新日期:2011-11-01 00:00:00
abstract::To evaluate the prevalence and indicators of hepatitis C virus (HCV) infection in Houston and determine the effectiveness of targeted HCV screening in sexually transmitted disease (STD) clinics. We performed a cross-sectional survey in low-risk and high-risk groups in Houston. This included a blinded survey of HCV con...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1046/j.1365-2893.2003.00410.x
更新日期:2003-03-01 00:00:00
abstract::The aim of this study was to evaluate the Chiron branched DNA (bDNA) assay for detection of serum hepatitis B virus (HBV) DNA in patients with chronic hepatitis B lacking hepatitis B e antigen (HBeAg) and undergoing interferon (IFN) therapy. Results obtained with the bDNA assay were compared with those obtained using ...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1046/j.1365-2893.1998.00128.x
更新日期:1998-11-01 00:00:00
abstract::Assessment and treatment for hepatitis C virus (HCV) in the community remains low. We evaluated factors associated with HCV specialist assessment and treatment in a cross-sectional study to evaluate treatment considerations in a sample of 634 participants with self-reported HCV infection in New South Wales, Australia....
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2010.01370.x
更新日期:2011-04-01 00:00:00
abstract::To assess the impact of sequential therapy with adefovir dipivoxil (ADV) and pegylated interferon alfa-2a (PEG-IFN) on virological (serum HBV-DNA) and serological (serum HBsAg) response in 20 consecutive HBeAg-negative patients. Patients received ADV for 20 weeks, then ADV and PEG-IFN for 4 weeks and lastly PEG-IFN fo...
journal_title:Journal of viral hepatitis
pub_type: 临床试验,杂志文章
doi:10.1111/j.1365-2893.2010.01332.x
更新日期:2011-08-01 00:00:00
abstract::DNA-based vaccination appears of promise for chronic hepatitis B immunotherapy, although there is an urgent need to increase its efficacy. In this preclinical study, we evaluated the therapeutic benefit of cytokine (IL-2, IFN-γ) genes co-delivery with DNA vaccine targeting hepadnaviral proteins in the chronic duck hep...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.12023
更新日期:2013-04-01 00:00:00
abstract::The association between HBV infection and incident thrombocytopenia among subjects without cirrhosis or splenomegaly is unknown. Therefore, we sought to elucidate the association between HBV infection and the development of thrombocytopenia in a large cohort of apparently healthy men and women. A cohort study was perf...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.12642
更新日期:2017-03-01 00:00:00
abstract::The optimal therapy for patients with chronic hepatitis C who have not responded to interferon (IFN) is still an unsolved issue. The aim of this study was to evaluate the efficacy and tolerability of a high dose of IFN-alpha2a plus amantadine for chronic hepatitis C patients who were non-responders to a previous cours...
journal_title:Journal of viral hepatitis
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1046/j.1365-2893.2001.00298.x
更新日期:2001-07-01 00:00:00
abstract::Chronic hepatitis C represents a major cause of progressive liver disease that can eventually evolve into cirrhosis and its end-stage complications. Formation and accumulation of fibrosis in the liver is the common pathway that leads to evolutive liver disease. Precise staging of liver fibrosis is essential for patien...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2011.01518.x
更新日期:2012-01-01 00:00:00
abstract::Portal hypertension and splenomegaly are common in patients with cirrhosis. However, there is limited previous in vivo research on the correlation between spleen stiffness and stages of liver fibrosis. This study aimed to evaluate the diagnostic value of spleen stiffness measurement (SSM), using acoustic radiation for...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2012.01588.x
更新日期:2012-09-01 00:00:00
abstract::We aimed to investigate the ability of HBsAg plasma level kinetics to predict therapy response by studying 23 children with infancy-acquired chronic hepatitis B (CHB) during combination sequential therapy with lead-in lamivudine (LAM) and add-on interferon-α (IFN-α) [5 responders (R = anti-HBs seroconversion) and 18 n...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.12316
更新日期:2015-04-01 00:00:00
abstract::Cholangiocarcinoma is the second most common liver cancer in the world. The aetiology of the disease is diverse incorporating a variety of conditions leading to biliary stasis, biliary and liver inflammation, but a large number of cases still occur in the absence of established risk factors. Its incidence and mortalit...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,评审
doi:10.1111/jvh.12093
更新日期:2013-05-01 00:00:00
abstract::We describe the epidemiology of hepatitis B virus (HBV) infection among women of reproductive age residing in areas of China that are highly endemic for chronic HBV, and provide evidence useful for decision-makers to guide strategies for preventing mother-to-child transmission of HBV, and assess the impact of perinata...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.12757
更新日期:2018-01-01 00:00:00
abstract::Response to interferon-alpha (IFN-alpha) treatment in hepatitis C is poorer when cirrhosis is present. In the third Australian multicentre hepatitis C trial, Aushep-3, we examined the efficacy and tolerability of an intensive 24-week course of interferon-alpha 2a in Child-Pugh grade A patients with chronic hepatitis C...
journal_title:Journal of viral hepatitis
pub_type: 临床试验,杂志文章,多中心研究
doi:10.1046/j.1365-2893.1997.00062.x
更新日期:1997-09-01 00:00:00
abstract::Serological and biochemical studies indicate that acute HBV infection is resolved in the context of an efficient cell-mediated immune (CMI) response, whereas, chronic infection is characterized by weak to undetectable CMI responses and relatively efficient humoral immunity. Because humoral immunity and CMI are regulat...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.1997.tb00180.x
更新日期:1997-01-01 00:00:00
abstract::In southwestern China, small but substantial numbers of patients with acute hepatitis were found without known hepatropic viral infections (hepatitis A, B, C, D or E, cytomegalovirus, Epstein-Barr virus) and were receiving no hepatotoxic drugs. Prevalence of antibodies, both neutralizing and specific immunoglobulin (I...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1046/j.1365-2893.1997.00140.x
更新日期:1997-07-01 00:00:00